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Abstract
Long-term infection caused by P. aeruginosa poses a major threat to personal & public health
and causes billions of dollars in medical expenses. To develop more effective controls, it is
important to accurately evaluate antibiotic susceptibility of clinical isolates and understand how
susceptibility changes during infection. Conventional drug susceptibility tests using nutrient-rich
media have been questioned regarding their relevance due to the difference between the model in
vivo test conditions and the environment in the patients. Here, we report that 27 clinical strains
of P. aeruginosa isolated from cystic fibrosis patients showed higher drug resistance in Artificial
Sputum Medium (ASM) than in the lab medium Lysogeny broth (LB) (up to 32 times). In
addition, the MIC of the clinical isolates from a patient shows different changes in antibiotic
susceptibility between LB and ASM. Specifically, when tested in LB, the ciprofloxacin MIC of
clinical strains from patient No. 5 gradually increased over the time of isolation. However, the
MIC of late isolates decreased in LB. In comparison, MIC continued to increase in ASM. This is
important to note because the ASM better represents the clinical condition of cystic fibrosis (CF)
patient. To better understand how P. aeruginosa adapts to the host airway environment, we
sequenced the genomes of P. aeruginosa strains chronically isolated from CF patients at Seattle
Children Hospital and compared with the wild-type PAO1. Several mutations were identified in
genes related to flagella, biofilm, intercellular communication, and antibiotic targets. In
summary, the findings from this study provide new insights into the development of antibiotic
resistance in P. aeruginosa and the importance to use appropriate in vitro testing methods, which
will help future research to control P. aeruginosa infections.

i

Antimicrobial susceptibility of P. aeruginosa clinical isolates

By
Tian Gao

B.S., Dalian University of Technology, 2008

Thesis
Submitted in partial fulfillment of the requirements for the degree of
Master of science in Bioengineering.

Syracuse University
December 2021

ii

Copyright by Tian Gao, 2021
All Rights Reserved

iii

ACKNOWLEDGMENTS

I would like to thank Dr. Ren for his invaluable guidance and insights in my thesis research. I
also thank Dr. Huan Gu for her training on experiments and sequence analysis. I am grateful to
Dr. Zafer Soultan at SUNY Upstate Medical University for sharing the clinical strains.

iv

Table of Contents
Copyright…………………………………………………………………………………………iii
Acknowledge…………………………………………………………………………………..…iv
List of Table…………………………………………………………………………….……...…vi
List of Figure…………………………………………………………………………………….vii
1.

Introduction ............................................................................................................................. 1

2.

Material and Method ............................................................................................................... 5
2.1 Preparation of Artificial Sputum Medium (ASM) ................................................................ 5
2.2 Determination of Minimum Inhibitory Concentration (MIC) .............................................. 6
2.3 Determination of Survival Percentage .................................................................................. 6
2.4 16S rRNA PCR ..................................................................................................................... 7
2.5 Use CLC Genomics Workbench to analyze clinical strain’s variation. ................................ 7
2.6 Motility test(swimming) ........................................................................................................ 7

3.

Result ....................................................................................................................................... 8
3.1 Antibiotics susceptibility of P. aeruginosa clinical isolates. ................................................. 8
3.2 Antibiotic Tolerance of P. aeruginosa clinical isolates. ...................................................... 11
3.3 16s rRNA PCR and sequencing .......................................................................................... 13
3.4 Whole genome sequencing of Washington strains. ............................................................ 14
3.5 Swimming Motility. ............................................................................................................ 21

4.

Discussion .............................................................................................................................. 21

5.

Conclusion and future work .................................................................................................. 24

References ……………………………………………………………………………………….26
Vita ………………………………………………………………………………………………31

v

List of Table

Table 1. MIC and persister percentage(ciprofloxacin) of Washington strain……………………15
Table 2. Variation screening process…………………………………………………………….16
Table 3. Changes in DNA and amino acid sequence of 22 variations in high persistence group.17
Table 4. Functions of 22 genes with variations in high persistence group………………………18
Table 5. Coding changes and amino acid changes of 14 variations in low persister…………….19
Table 6. Functions of the 14 genes that have variations in the high persistence group…...…….20
Table 7. Swimming motility test result of Washington strain……………………………….….21

vi

List of Figure

Figure 1. MIC of clinical strains………………………………………………………………...10
Figure 2. Ciprofloxacin tolerance of isolates from patients 5 and 7………………………..…...12
Figure 3. Ciprofloxacin & tobramycin tolerance of isolates from of rest clinical strains……….13
Figure 4. PCR amplification results of 16S rRNA of PAO1, PA5a, and PA5f……………..….14

vii

1. Introduction
P. aeruginosa is a Gram-negative bacterium commonly inhabiting the lungs of patients with
cystic fibrosis (CF), various wounds, and diabetic ulcers (1)(2)(3). It is an "opportunistic"
bacterium that usually affects patients with weakened immune functions (4). The adaptability of
P. aeruginosa enables it to survive in various natural and manmade environments, including the
surface of medical devices (5). This makes it one of the most common agents causing hospital
acquired inflection (6). P. aeruginosa has developed mechanisms to resist a variety of antibiotics,
which makes its infection difficult to treat and leads to high morbidity and mortality. According
to the Centers for Disease Prevention and Control (CDC), P. aeruginosa caused 32,600
hospitalizations and $767 million of healthcare cost in 2017. Considering chronic diabetic ulcers
and other related diseases, P. aeruginosa related treatment costs the US healthcare system will
reach 50 billion dollars (7). In view of the harmfulness of P. aeruginosa infections and the
increasing resistance to antibiotics, it is urgent to understand its resistance mechanism and
discover strategies for prevention and treatment（3）.

Resistance refers to the reduced effectiveness of a drug in treating a disease or condition (8).
Antibiotics have specific targets and mutations in those targets will interfere with or destroy
antibiotics, leading to antibiotic resistance (9). On the other hand, pathogens may develop
resistance to more than one drug, causing multidrug resistance. Multiple mechanisms are known
to cause antibiotic resistance. P. aeruginosa can modify the binding site targeted by antibiotics or
use enzymes to modify the antibiotic molecules to neutralize it or use the efflux pumps to
extrude the antibiotics (10). Alexander Fleming used the measurement of the turbidity of the
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broth that changes with the concentration of antibiotics to study drug resistance. This is
considered as the pioneer of minimum inhibitory concentration (MIC) test (11). In 1940s,
Schmith & Reymann first described the antimicrobial susceptibility testing (AST) theory and
determined MICs of sulphapyridine for gonococci. (11) The use of non-lethal levels of
antibacterial agents, especially at concentrations lower than MIC, will provide selective pressure
to drive the evolution of pathogen resistance in the direction of resistance (12). Currently, many
pathogens (including P. aeruginosa) have gradually acquired resistance to antibacterial agents to
which they were previously susceptible. Therefore, in the context of multidrug-resistant bacteria,
appropriate use of antibiotics is particularly important. Although MIC widely used in clinical
tests and drug discovery, it has two major limitations. First, MIC cannot distinguish tolerance
from resistance. (High tolerance strains may have the same MIC as sensitive strains.) Secondly,
the validity of the data in in vitro experiments is affected to a certain extent due to the difference
between the culture medium and the in vivo environment (13).
In addition to resistance with elevated MIC, bacteria could survive high concentration of
antibiotics though the mechanism of tolerance (14, 15). A major mechanism of tolerance is due
to non-growth or slow growth ability of bacteria. Under short-term antibiotic exposure, some
bacteria survived antibiotic treatment through this mechanism, and they resumed exponential
growth after the quiescent period without any change in MIC. However, if bacteria are frequently
and intermittently exposed to antibiotics, they can develop resistance with increased MIC.
Because tolerance does not change MIC, it is often being ignored in clinical practice, and
eventually leads to antibiotic abuse and the development of highly resistant bacteria over time
(16).
In 1944, Joseph Bigger discovered that a small number of bacterial populations survived
2

penicillin treatment but maintained their sensitivity to penicillin in MIC test. He named these
surviving bacterial cells persisters. With the development of single-cell analysis technology,
some scientists question the definition, and try to redefine and reach consensus on the basic
definition of persistence and the survival mechanism of bacterial populations from multiple
perspectives (17) (18). At present, persistence is considered heterogeneous: unlike tolerance,
persistence is not the general ability of bacterial populations, but an additional attribute
possessed by a small number of bacterial subgroups (17). At present, the mechanism of
persistence is not clear, but some studies believe that its dormancy and reduced metabolism
mechanisms are related to tolerance (19).
The multiple mechanism of resistance, tolerance and persistence of P. aeruginosa make its
infections difficult to content. In the CF airway, P. aeruginosa forms biofilm with cell
aggregates, which reduce the ability of antibiotics (20). CF Patients with mutations in the gene of
transmembrane conductance regulator (CFTR), usually have chronic infections by P. aeruginosa,
which leads to worsening lung inflammation high mortality (20) (21) (22). Previous research
showed that CFTR modulating therapy has no significant effect on P. aeruginosa (23). On the
other hand, physical destruction of biofilm can restore the sensitivity of P. aeruginosa to
antibiotics and the immune system (24) (25).
In vitro models are preferred in most studies on bacterial resistance, tolerance, and persistence.
Biofilm experiments also rely heavily on in vitro models due to low cost and high throughput of
these model. However, there are increasing reports that showed differences in the results
between vitro models and the in vivo models. This is mainly because the in vitro models do not
accurately simulate the in vivo microenvironments of disease conditions (26). For example, rich
media such as LB are usually used in in vitro models, which are considered to lack key factors
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such as mucin and eDNA compared with in vivo. This results in a lack of the extracellular matrix
in biofilms in in vitro models. Ultimately, these differences affect the accuracy of the in vitro test
data.
To better mimic the CF condition, Sriramulu et al. developed an artificial sputum culture
medium (ASM) containing mucin, DNA, lecithin and a variety of amino acids to simulate the
sputum of the CF airway (27). Their study found that P. aeruginosa produced compact small
colonies and more extracellular matrix in ASM, compared with the medium without the above
components. The in vitro model based on ASM is a low-cost, high-throughput research method,
and a simple and reproducible alternative to the in vivo model of P. aeruginosa (28). Besides P.
aeruginosa, ASM is also used in the study of other bacteria, such as S. maltophillia (29). ASM
does have its shortcomings: For example, compared with LB (0.05OD), ASM has a high
turbidity (0.4～0.6OD). This is mainly because ASM contains mucin, DNA and other
components that are insoluble in aqueous solution. And, since these components will degrade
over time, the turbidity of ASM will also change over time. Therefore, the traditional MIC test,
based on turbidity conversion, is not suitable for ASM. Resazurin is a weakly fluorescent dye
that can be used as a redox indicator and is reduced by metabolically active cells in the culture
medium to resorufin with pink color and strong fluorescence(590/25nm) (30). The Resazurin
Microtiter Analysis (REMA) plate method developed based on this characteristic can be used for
the determination (MIC) (31). Second, resazurin has one of the maximum values of the known
Clift dichroic index, which means concentration of observed sample increasing or decreasing
will cause a large change in its color (32). Further research on resazurin showed that resazurin
has no obvious toxicity to cells within the specified analysis time and can be used for nondestructive experiments in vitro determination (33).
4

At present, studies have focused on the optimization of in vitro culture media to simulate the
formation of in vivo biofilms, but there is a lack of research on the effect of ASM on the
resistance, tolerance and persistence of P. aeruginosa. Our goal is to study the development of
drug resistance, tolerance and persistence of clinical strains on the basis of ASM, and to compare
the effects of ASM and LB media on these properties. Additionally, we compared the genome
sequence of clinical isolates to identify mutations in key gene related to resistance, tolerance and
persistence.

2. Material and Method
2.1 Preparation of Artificial Sputum Medium (ASM)
First, 800 ml of distilled water was put in a beaker and placed on a magnetic stirring plate. Then
5 g mucin from porcine stomach (type II) (Sigma), 4 g low molecular-weight salmon sperm
DNA (Fisher Scientific), 5.9 mg diethylene triamine Penta acetic acid (DTPA), 5 g NaCl and 2.2
g KCl, and 1.81 g Tris base were added with constant stirring. Add 250 mg of each amino acid
except tryptophan (Fisher Scientific). The pH of the medium was adjusted to 7.0 using Tris base
during mixing. After mixing, the final volume of the medium was adjusted to 1000 mL with DI
water. The medium was sterilized in an autoclave at 110oC for 40 minutes. After cooling to room
temperature, filter-sterilized tryptophan was added to the final concentration of 250 mg/L.
Finally, 5 ml of egg yolk(The eggs used are sterilized by alcohol) emulsion was add. ASM
should be stored at 4 degrees Celsius and protected from light.
5

2.2 Determination of Minimum Inhibitory Concentration (MIC)
Overnight cultures of P. aeruginosa in LB was used to inoculate subcultures to an OD600 of
0.005 and added to a 96-well plate containing 200 µL culture in each well supplemented with
serially diluted antibiotic of interest. The final concentrations of antibiotics ranged from 0.125 64 μg/mL. Negative control wells were also included for each isolate, which did not have any
antibiotic added. One well with medium only was included as a blank control. The 96-well plates
were incubated for 24 h at 37 °C with shaking at 200 rpm. Ten μL of 0.05 % (v/v) resazurin (in
DI water) was added to each well of the 96-well plates and incubated for 1 h at 37 °C with
shaking at 200 rpm. Following incubation with resazurin, fluorescence of each well was
monitored with an excitation wavelength of 530 nm and an emission wavelength of 590 nm
using a fluorescence plate reader (Biotek Synergy 2 plate reader). The minimum inhibitory
concentration of the antibiotic was determined based on the first well in which no bacterial
growth was observed after xxx hours.
2.3 Determination of Survival Percentage
An overnight culture of P. aeruginosa in LB were used to inoculate subcultures to an OD600 of
0.1 in 24-well plate with 2mL culture in each well. The antibiotic to be tested was added to each
well at 64 µg/mL. Negative control wells were included for each isolate, in which no antibiotic
was added. One well with medium only was also included as a blank control. Three replicates of
each condition were tested. The 24-well plates were incubated for 3.5 h at 37 °C with shaking
at75 rpm. Then, 1 mL of each sample was transferred to a 1.5 mL tube and washed 3 times with
PBS (centrifuge at 5min, 13,200 rpm after each washing step). After a serial 10x dilution, the
samples were analyzed for CFU by dropping 10 µL of each sample on a LB agar plate. The
6

survival rate of P. aeruginosa in the corresponding antibiotic treatment was determined based on
the number of colonies after overnight incubation.
2.4 16S rRNA PCR
Prepare PCR sample solution: Each PCR reaction was set up with a total volume of 50 µL in a
thin walled 0.2 mL PCR tubes. Reagents were added in the following order: 38.5 µL (RNAasefree water, 5µL 10X PCR buffer, 4 µL dNTPs, 1.25 µL primers, 0.5 µL DNA template, 0.25 µL
Taq polymerase. Gently mix by tapping tube. Briefly centrifuge to settle tube contents.
Running PCR:
The PCR reaction included initial denaturation at 95 °C for 2 min, followed by xx cycles
including denaturation at 95 °C for 30 sec, annealing at 55 °C for 45 sec, and elongation at 72 °C
for 4 min. After final elongation at 72 °C for 7 min, the sample was stored at 4 °C until further
processing.
2.5 Use CLC Genomics Workbench to analyze clinical strain’s variation.
The raw data of whole genome sequencing were trimmed to remove adaptors before assembly.
Reference-guided assembly was performed by using the PAO1 genome as reference to identify
variation. The variants that had minimum variation frequency lower than 100%, average quality
lower than 30%, or silent variations that do not cause amino acid changes were excluded. The
results were exported to Excel for summary.
2.6 Motility test(swimming)
First, 0.3% LB agar plates were prepared. A 10 µL of culture (OD600 of 0.1) was added in the
7

middle of the plate. The plate was covered with Saran Wrap to prevent dehydration. After
incubation at 37°C for 24 h, the diameter of the colony was measured to evaluate the swimming
motility.
3. Results
3.1 Antibiotics susceptibility of P. aeruginosa clinical isolates.
Recently, we isolated 28 P. aeruginosa clinical strains from University Hospital of Syracuse.
These clinical strains were isolated from different patients during their return visits. The strains
were named according to patient de-identified date of isolation and strain morphology. For
example, PA5d1 represents non-mucoid strain in the 4th sample of patient NO. 5. To test the
development of resistance of these clinical isolates, we evaluated the MIC for ciprofloxacin and
tobramycin for each strain. Similarly, in order to test whether the culture medium influences drug
resistance, we compared the MIC of these clinical isolates in LB and ASM. The wild-type strain
PAO1 was used as control group. 25 clinical strains and PAO1 in ASM have a higher MIC of
ciprofloxacin than in LB. In contrast, 7 clinical strains have a higher tobramycin MIC in ASM,
and the MIC of 20strains remains unchanged, and the MIC of a clinical strain is higher in LB
than in ASM.
The first isolate PA5a from patient 5 has the same ciprofloxacin MIC as wild type PAO1
(0.25µg/ml in LB, 1µg/ml in ASM), which means that they are both sensitive to ciprofloxacin.
MIC above 8µg/ml is defined as resistance. The MIC of ciprofloxacin of PA5b1, PA5c1, and
PA5d1 gradually increased both in LB and ASM, and the MIC of PA5c1 and PA5d1 exceeded
the threshold of ciprofloxacin resistance. After that, the MIC of PA5e, PA5f, PA5g, and PA5h
showed different trends in LB and ASM. In ASM, PA5e and PA5g showed higher resistance
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(compared to PA5d1). In contrast, their MICs in LB are lower than PA5d1. PA5f is an
interesting clinical strain. It has the same MIC as PAO1, but other isolates around it keep
resistance. The MIC of ciprofloxacin of the clinical strain of patient 7 also showed a gradual
increase in MIC. The early isolates PA7a1, PA7a2, and PA7a3 have ciprofloxacin MIC similar
to that of PAO1, and they are all sensitive to ciprofloxacin. The MIC of subsequence isolate
PA7d exceeded the threshold, showing resistance to ciprofloxacin. Regarding tobramycin, the
MIC of patient No. 5 and patient No. 7 did not show changes over time among the tested strains.
On the other hand, unlike the MIC of ciprofloxacin in LB and ASM, the MIC of tobramycin
isolated from patients No. 5 and No. 7 was basically the same or similar in LB and ASM (PA5h
exception). In addition, the number of return visits for other patients was less than 3 times. The
MICs of these 13 clinical strains in LB and in ASM also showed similar trends to the clinical
strains of patients No. 5 and No. 7: The MICs of ciprofloxacin in different media are quite
different. MICs of tobramycin are similar.
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Figure 1. MIC of clinical strains
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3.2 Antibiotic Tolerance of P. aeruginosa clinical isolates.
Unlike resistance that is based genetic elements, tolerance is phenotype. However, tolerance has
the same clinical presentations, e.g., the patients are not responsive to antibiotics. The study by
Kester et al. (17) found that tolerance is usually neglected in clinical research, and the resulting
abuse of antibiotics may lead to the emergence of highly resistant clinical strains. This motivated
us to test the percentage of clinical strains surviving different antibiotic concentrations and
compare that with MIC. We first tested the tolerance to 64µg/ml ciprofloxacin. Compared with
the wild-type PAO1, isolates from patient No. 5 showed higher tolerance in both LB and ASM.
But unlike the MIC results, tolerance was not always higher in ASM than in LB. Because,
64µg/ml is close to the MICs of some clinical strains, e.g., PA5e, PA5g, we further tested
ciprofloxacin of 200µg/mL. This treatment killed all isolates by more than 90%, except for
PA5d1 and PA5g which showed level tolerance. The tolerance of isolates from patient 5 did not
show a clear change over time. Interestingly, tolerance to 200µg/ml ciprofloxacin was found
lower in ASM than LB for isolates from patient No. 5 in ASM is slightly lower than that in LB.
Similar results were obtained from isolates from patient No. 7.
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Figure 2. Ciprofloxacin tolerance of isolates from patients 5 and 7

We also tested tolerance to tobramycin. All clinical isolates showed similar or higher tolerance
than the wild-type PAO1.
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Figure 3. Ciprofloxacin & tobramycin tolerance of isolates from of rest clinical strains

3.3 16s rRNA PCR and sequencing
To verify the clinical isolates are indeed P. aeruginosa we selected several clinical strains of
PA5a, PA5b1, PA5e, PA5f, and PA5g to sequence the 16S rRNA of P. aeruginosa. The
sequences were submitted to NVBI database.
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Figure 4. PCR amplification results of 16S rRNA of PAO1, PA5a, and PA5f

BLAST results showed that all 16S rRNA sequence 99.62% identify of PAO1, much higher than
the second match, the 16S rRNA of Azotobacter chroococcum, with an identify of 96.65%. This
confirmed that those clinical strains are deed P. aeruginosa.
3.4 Whole genome sequencing of Washington strains.
In a complementary study, we conducted whole genome sequencing of chronically isolated
strains from Seattle Children’s hospital. Six strains were ordered in our analysis They were
divided into two groups according to the tolerance. Group 1 exhibited 100 to 1600 times higher
tolerance than Group 2 strains. The strains in Group 1 also had a higher MIC (10 to 30 times)
than t Group 2 strains (Table 1). Genetic DNA of the six strains were isolated and recessed. CLC
Genomics Workbench (QIAGEN Bioinformatics, Hilden, German) was used to analyze wholegenome sequencing data. We used reference-guided assembly to analyze the 50X depth of the
whole genome sequence. This is a method uses a known genome as a reference to assemble
sequence data (1). We chose the PAO1 genome (AE004091) as the reference and compared the
assembly genomes to identify variants.

14

Table 1. MIC and persister percentage(ciprofloxacin) of Washington strain

Strain

MIC(µg/ml)

Persister percentage (%)

PA4(0048-78)

10

10%

PA5(0048-28)

4

6%

PA9(0148-38)

2

3%

PA6(0148-39)

0.3

0.004%

PA8(0148-37)

0.3

0.03%

PA12(0145-4)

0.3

0.006%

To ensure the quality of data analysis, we screened out the variations with the smallest variation
frequency below 100% and the average quality below 30%. We also excluded the silent
variations that do not result in amino acid changes. With this approach, we identified about 2048
to 3719 variations in each clinical strain. Subsequently, we further screened out the variations
that occurred in the known GO-term, which facilitated us to predict the possible impact of the
variation. This also reduced the number of variations to 438 to 657. We found 22 shared
variations among the three strains that form lager number of persisters but are absent in all three
strains that form less persisters (Group 2). Additionally, we also identified 14 variants that are
only present in the low persistence group. (Table 2)
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Table 2. Variation screening process

Strain

Variation
(amino acid change)

Variation
(GO-term)

PA4(0048-78)

3274

657

PA5(0048-28)

3301

602

PA9(0148-38)

2932

472

PA6(0148-39)

2408

438

PA8(0148-37)

3115

466

PA12(0145-4)

3719

612

Variation
(only in same group)
22

14

Among the 22 variations of high persistence group, 14 variations are related to flagellum and the
rest are related to biofilm formation, cell communication, and cellular response to oxygen levels,
cell adhesion (Table 3, Table 4).
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Table 3. Changes in DNA and amino acid sequence of 22 variations in high persistence
group

Gene name

Coding region change

Amino acid change

flgK

AAG04475.1:c.133A>G

AAG04475.1:p.Ile45Val

flgK

AAG04475.1:c.1984A>G

AAG04475.1:p.Ser662Gly

flgL

AAG04476.1:c.170C>G

AAG04476.1:p.Ala57Gly

flgL

AAG04476.1:c.335C>G

AAG04476.1:p.Thr112Ser

motC

AAG04849.1:c.29T>C

AAG04849.1:p.Ile10Thr

ccmA

AAG04864.1:c.544A>G

AAG04864.1:p.Thr182Ala

lasA

AAG05260.1:c.34C>T

AAG05260.1:p.Pro12Ser

braZ

AAG05359.1:c.1181A>G

AAG05359.1:p.Asp394Gly

pqqF

AAG05361.1:c.1810G>A

AAG05361.1:p.Val604Met

PA2077

AAG05465.1:c.1550A>G

AAG05465.1:p.Asp517Gly

cupA3

AAG05518.1:c.377G>A

AAG05518.1:p.Gly126Asp

cupA4

AAG05519.1:c.868T>C

AAG05519.1:p.Ser290Pro

PA2652

AAG06040.1:c.784T>C

AAG06040.1:p.Tyr262His

cif

AAG06322.1:c.855C>G

AAG06322.1:p.Asp285Glu

pelB

AAG06451.1:c.772C>G

AAG06451.1:p.Gln258Glu

pilB

AAG07914.1:c.219_221delCAAinsTCG

AAG07914.1:p.Lys74Arg

fimT

AAG07937.1:c.323T>G

AAG07937.1:p.Leu108Arg

pilW

AAG07940.1:c.422_423delCTinsGG

AAG07940.1:p.Ala141Gly

pilW

AAG07940.1:c.430C>G

AAG07940.1:p.Gln144Glu

pilW

AAG07940.1:c.432G>C

AAG07940.1:p.Gln144His

pilY1

AAG07942.1:c.11T>C

AAG07942.1:p.Val4Ala

estA

AAG08497.1:c.1601C>G

AAG08497.1:p.Thr534Ser

.
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Table 4. Functions of 22 genes with variations in high persistence group

Gene name

Function

flgK

bacterial-type flagellum assembly

flgL

bacterial-type flagellum assembly

motC

bacterial-type flagellum-dependent swarming motility, bacterial-type flagellumdependent cell motility
cytochrome complex assembly

ccmA
lasA
braZ

proteolysis, protein secretion by the type II secretion system, protein transport by
the Sec complex
branched-chain amino acid transport

pqqF

pyrroloquinoline quinone biosynthetic process

PA2077

oxylipin biosynthetic process

cupA3

pathogenesis, cell aggregation, cellular response to oxygen levels, cell adhesion

cupA4

pathogenesis, cellular response to oxygen levels

PA2652

positive chemotaxis, chemotaxis, cellular response to organic substance

cif

pilB

pathogenesis, negative regulation of chloride transport, negative regulation of
ubiquitin-specific protease activity
single-species biofilm formation, extracellular polysaccharide biosynthetic process,
polysaccharide transport
type IV pilus-dependent motility, type IV pilus biogenesis

fimT

type IV pilus biogenesis

pilW

type IV pilus-dependent motility, pilus assembly, type IV pilus biogenesis

pilY1

type IV pilus-dependent motility

estA

bacterial-type flagellum-dependent swarming motility, single-species biofilm
formation, bacterial-type flagellum-dependent cell motility, glycolipid biosynthetic
process

pelB
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In contrast, among the 14 variations in the low persistence group, only 2 changes are related to
type IV pili, and others are most related to cell metabolism(biosynthetic process, metabolic
process (Table 5, Table 6).
Table 5. Coding changes and amino acid changes of 14 variations in low persister
percentage group.

Gene name

Coding region change

Amino acid change

cobD

AAG04664.1:c.143C>G

AAG04664.1:p.Ala48Gly

cobC

AAG04665.1:c.103T>C

AAG04665.1:p.Ser35Pro

aphA

AAG04798.1:c.184C>A

AAG04798.1:p.Leu62Ile

pscO

AAG05085.1:c.280G>A

AAG05085.1:p.Ala94Thr

lpdV

AAG05638.1:c.208A>G

AAG05638.1:p.Ser70Gly

opmQ

AAG05779.1:c.443A>G

AAG05779.1:p.Gln148Arg

PA4108

AAG07495.1:c.433C>G

AAG07495.1:p.Leu145Val

fepB

AAG07546.1:c.626A>G

AAG07546.1:p.Gln209Arg

pctA

AAG07697.1:c.1663A>G

AAG07697.1:p.Ser555Gly

ureA

AAG08250.1:c.194A>G

AAG08250.1:p.Asn65Ser

pilQ

AAG08425.1:c.316G>A

AAG08425.1:p.Ala106Thr

PA5132

AAG08517.1:c.270T>G

AAG08517.1:p.Ser90Arg

glmS

AAG08934.1:c.283G>C

AAG08934.1:p.Val95Leu

glmR

AAG08935.1:c.709T>C

AAG08935.1:p.Ser237Pro
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Table 6. Functions of the 14 genes that have variations in the high persistence group

Gene name

Function

cobD

cobalamin biosynthetic process

cobC

cobalamin biosynthetic process

aphA

polyamine metabolic process, putrescine biosynthetic process

pscO

protein secretion by the type III secretion system

lpdV

oxoacid metabolic process, cellular amino acid metabolic process

opmQ

pyoverdine biosynthetic process

PA4108
fepB

regulation of single-species biofilm formation on inanimate substrate, positive
regulation of cell motility
ferric-enterobactin transport

pctA

chemotaxis, response to amino acid

ureA

urea catabolic process

pilQ

type IV pilus biogenesis

PA5132

CAAX-box protein maturation

glmS

UDP-N-acetylglucosamine biosynthetic process

glmR

positive regulation of cilium assembly, negative regulation of transcription, DNAtemplated, positive regulation of cell motility, regulation of polysaccharide
biosynthetic process

The above findings support the argument that functions of cell motility and biofilm formation
may be related to the high persistence of clinical strains. Another interesting point is that in the
low persistence group, we found that these clinical strains shared one variation on both glmS and
glmR. Recent studies have shown that these two genes are related to the antibiotic binding sites
of bacteria and parasites, and variations may increase their antibiotic sensitivity. (34,35)
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3.5 Swimming Motility.
As mentioned above, we found that more than half of the unique genetic variations in the high
persistence group are related to flagella, while only 2 variations in the low persistence group are
related to motility. To verify if these strains have impaired motility, we performed swimming
motility tests on all isolates and used wild-type PAO1 as control. Based on the swimming plate
tests, the cells from high persistence group do not have significant change in swimming motility
compared to PAO1. Two strains in the low persistence group have either increased (PA12) or
decreased (PA8) motility (Table 7).
Table 7. Swimming motility test result of Washington strain

Strain

Colony diam (mm)c after 24 h

PAO1

23 ± 1

PA4(0048-78)

22 ± 1

PA5(0048-28)

23 ± 1

PA9(0148-38)

19 ± 1

PA6(0148-39)

23 ± 1

PA8(0148-37)

6±1

PA12(0145-4)

67 ± 1

4. Discussion
Biofilm-mediated drug resistance and the formation of a multi-drug tolerant persister cells lead
to recurrence of P. aeruginosa infection, despite aggressive antibiotic treatment (36). P.
aeruginosa is the leading cause of morbidity, mortality and medical care costs of CF patients
worldwide. There is a growing demand for alternative treatment strategies that are more effective
against P. aeruginosa (36). This requires test methods that accurately represent the in vivo
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condition in CF patients. Current methods rely on rich media, which is drastically different from
the environment in CF airways. These obvious differences challenge the relevance of related
tests that use rich lab media (37).
In this study, we isolated 27 P. aeruginosa strains from the University Hospital in Syracuse,
some of which were isolated from the same patient’s over repeating visits. Most of these 27
clinical strains exhibited different MICs between LB and ASM. Twenty-five clinical strains had
higher ciprofloxacin MIC in ASM than in LB, and the other two had the same ciprofloxacin MIC
between these two media. Specially, the MIC of ciprofloxacin of some clinical strains (PA10a1,
PA10a2) in ASM is more than 30 times that in LB. We noticed that in the MIC test, P.
aeruginosa formed visible clumps (cell aggregates) in ASM. This phenomenon occurs in both
wild-type strains PAO1 and clinical strains at the same time, which is the same as the results of
Kirchner S et al. (31) In addition, these visible clumps were also found in samples (e.g.,
64µg/ml) with high ciprofloxacin concentration where resazurin dye showed no metabolic
activity. On the other hand, these visible clumps were not found in LB. The lung sputum of CF
patients contains mucin, amino acids, and DNA released by neutrophils. It is well known that P.
aeruginosa develops biofilm with suspended microcolonies in such an environment. ASM also
contains these factors, but LB does not. This may explain why clumps owe seen in ASM only.
This may also contribute to the high-level MIC and tolerance observe than in LB.
One interesting finding is the change in the MIC of ciprofloxacin in the strains isolated from
patient 5. Patient No. 5 had more return visits. The hospital isolated 8 strains from patient 5. The
first isolate PA5a had the same MIC as the wild-type strain PAO1, both in LB and ASM. The
MICs of PA5b1, Pa5c1, and PA5d1 isolated three times later showed a gradual increase in MIC.
The subsequent MICs of PA5e, PA5f, PA5g, and PA5h in LB decreased, but PA5e and PA5g
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had continuous increase in MIC in ASM. In general, the ciprofloxacin MIC of the clinical
isolates from patient No. 5 showed different trends in different media: it increased and then
decreased in LB, but the MIC of some strains in ASM show continuous increase over time. Since
ASM better simulates the CF airway than LB, these results emphasize the importance of using
appropriate medium for antibiotic test. Using in appropriate medium like LB can misinform
clinicians about the choice of antibiotics. On the other hand, the MIC of ciprofloxacin of 6
clinical strains of patient No. 7 also showed a trend of increasing with the isolation time both in
ASM and LB.
We also compared the MIC of Tobramycin in LB and ASM. One third of clinical strains have
different MICs between LB and ASM. The MIC of wild type PAO1 showed no different
between LB and ASM. Unlike cipro results, the differences in MIC of clinical strains were all
within 4-fold. This indicates that the CF airway my affect the efficacy of different antibiotics
differently.
In the tolerance did not show the same trend as MIC. For cells collected during exponential
growth, the clinical isolates from patient No. 5 showed similar levels of tolerance. Although
PA5a has the same MIC as the wild type PAO1, its persistence was more than 30 times higher to
200ug/ml ciprofloxacin. Patient No. 7 showed different results. For exponential cells clinical
strains and wild-type strain had similar levels of persistence. Specifically, after 200ug/ml
ciprofloxacin treatment, the clinical strains of patient No. 5 and patient No. 7 had similar level of
persistence between LB and ASM. Further studies are needed to determine non tolerance affects
resistance and if tolerance needs to develop first.
Based on the DNA sequencing analysis, most of the common genetic variations in the high
resistance group are related to flagella, biofilm formation and cell-to-cell communication. The
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variations in the low tolerance percentage group are mostly related to cell metabolism and
antibiotic binding sites, especially the variations in the genes of glmS and glmR. Recent studies
suggest that they are related to antibiotic susceptibility of P. aeruginosa to antibiotics. This is
consistent with the finding that the low persistence group has low MICs. Similarly, variations in
genes related to cell metabolism may affect the dormancy of P. aeruginosa, resulting in low
persistence.
Because the high persistence group shared 14 common variants related to flagellar genes, and the
low persistence group had 2 type IV pilus related variations, we also performed swimming
motility tests on these isolates. The results showed did not reveal a clear correlation between
motility and antibiotic tolerance. However, there are other types of motilities that involve
flagellar and pili such twitching, swarming, gliding, Etz. It will be interesting to further compare
these motilities among the 6 isolates.
5. Conclusion and future work
In summary, we isolated 27 CF clinical strains from the University hospital in Syracuse. These
strains showed higher ciprofloxacin MIC in ASM than in LB, although the patients vary in the
trend of MIC among the strains isolated over time. Because ASM has the factors that are present
in the patient's sputum, and these factors help P. aeruginosa produce more extracellular matrix,
ASM is a better medium for clinical strains. The mechanism that leads to increase in antibiotic
tolerance of P. aeruginosa clinical strains in ASM is currently unclear, and further research is
needed. The results of DNA sequencing analysis of clinical strains from Washington University
indicate that the persistence of P. aeruginosa may be the result of multiple mutations. Further
testing involving more isolates would help reveal how this airborne opportunistic pathogen
adapts to CF airway. Motility test did not reveal a condition between flagella gene mutation and
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antibiotic susceptibility. It will be helpful to test other motilities especially those isolates from
the same patients over time.
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